Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 4A10 |
| Synonyms | |
| Therapy Description |
4A10 is a monoclonal antibody targeting CD127, which potentially inhibits IL-7 signaling and induces antibody-dependent cellular cytotoxicity and phagocytosis and inhibits tumor cell proliferation (Cancer Res (2025) 85 (8_Supplement_1): 7044). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 4A10 | 4-A10|4A-10 | 4A10 is a monoclonal antibody targeting CD127, which potentially inhibits IL-7 signaling and induces antibody-dependent cellular cytotoxicity and phagocytosis and inhibits tumor cell proliferation (Cancer Res (2025) 85 (8_Supplement_1): 7044). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07586618 | Phase I | 4A10 | First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect. (ALT-101) | Recruiting | USA | 0 |